- TRADE NAMES: Daranide; Keveyis (Taro)
- INDICATIONS: Glaucoma (Daranide), primary hyperkalemic or hypokalemic periodic paralysis (Keveyis)
- CLASS: Carbonic anhydrase inhibitor
- HALF-LIFE: 8 minutes
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aspirin, Cyclosporine, Diflunisal, Lithium, Metformin, Primidone, Salicylates, Salsalate
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
